Max Robinson

Dr. Max Robinson

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2021 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
TWTomasz Wilmanski
Tomasz Wilmanski
CDChristian Diener
Christian Diener
NRNoa Rappaport
Noa Rappaport
SPSushmita Patwardhan
Sushmita Patwardhan
JWJack Wiedrick
Jack Wiedrick
NPNathan Price
Nathan Price

1 March 1997 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HYHiroki Yokota
Hiroki Yokota
FJForrester Johnson
Forrester Johnson
HLHongbo Lu
Hongbo Lu
MRMax Robinson
Max Robinson
ABAnna M. Belu
Anna M. Belu
DMDavid L. Miller
David L. Miller
We have developed an improved method of straightening DNA molecules for use in optical restriction mapping. The DNA was straightened on 3-aminopropyl-triethoxysilane-coated glass slides using surface tension generated by a moving meniscus. In our method the meniscus motion was controlled mechanically, which provides advantages of speed and uniformity of the straightened molecules. Variation in the affinity of the silanized surfaces for DNA was compensated by precoating the slide with single-stranded non-target blocking DNA. A small amount of MgCl 2 added to the DNA suspension increased the DNA-surface affinity and was necessary for efficient restriction enzyme digestion of the straightened surface-bound DNA. By adjusting the amounts of blocking DNA and MgCl 2 , we prepared slides that contained many straight parallel DNA molecules. Straightened λ phage DNA (48 kb) bound to a slide surface was digested by Eco RI restriction endonuclease, and the resulting restriction fragments were imaged by fluorescence microscopy using a CCD camera. The observed fragment lengths showed excellent agreement with their predicted lengths.

1 December 1996 in Genomics
Verified
Journal Article
Closed access
ESEugene G. Shpaer
Eugene G. Shpaer
MRMax Robinson
Max Robinson
DYDavid Yee
David Yee
JCJames D. Candlin
James D. Candlin
RMRobert Mines
Robert Mines
THTim Hunkapiller
Tim Hunkapiller

6 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GGGwênlyn Glusman
Gwênlyn Glusman
JPJuan Caballero Perez
Juan Caballero Perez
MRMax Robinson
Max Robinson
BKBurak Kutlu
Burak Kutlu
LHLeroy Hood
Leroy Hood
Deep sequencing of transcriptomes has become an indispensable tool for biology, enabling expression levels for thousands of genes to be compared across multiple samples. Since transcript counts scale with sequencing depth, counts from different samples must be normalized to a common scale prior to comparison. We analyzed fifteen existing and novel algorithms for normalizing transcript counts, and evaluated the effectiveness of the resulting normalizations. For this purpose we defined two novel and mutually independent metrics: (1) the number of “uniform” genes (genes whose normalized expression levels have a sufficiently low coefficient of variation), and (2) low Spearman correlation between normalized expression profiles of gene pairs. We also define four novel algorithms, one of which explicitly maximizes the number of uniform genes, and compared the performance of all fifteen algorithms. The two most commonly used methods (scaling to a fixed total value, or equalizing the expression of certain ‘housekeeping’ genes) yielded particularly poor results, surpassed even by normalization based on randomly selected gene sets. Conversely, seven of the algorithms approached what appears to be optimal normalization. Three of these algorithms rely on the identification of “ubiquitous” genes: genes expressed in all the samples studied, but never at very high or very low levels. We demonstrate that these include a “core” of genes expressed in many tissues in a mutually consistent pattern, which is suitable for use as an internal normalization guide. The new methods yield robustly normalized expression values, which is a prerequisite for the identification of differentially expressed and tissue-specific genes as potential biomarkers.

7 January 2016 in Human Genome Variation
Verified
Journal Article
Open access
PDF file
ASAnna B Stittrich
Anna B Stittrich
JAJustin Ashworth
Justin Ashworth
MSMude Shi
Mude Shi
MRMax Robinson
Max Robinson
DMDenise Mauldin
Denise Mauldin
GGGwênlyn Glusman
Gwênlyn Glusman
Currently, the best clinical predictor for inflammatory bowel disease (IBD) is family history. Over 163 sequence variants have been associated with IBD in genome-wide association studies, but they have weak effects and explain only a fraction of the observed heritability. It is expected that additional variants contribute to the genomic architecture of IBD, possibly including rare variants with effect sizes larger than the identified common variants. Here we applied a family study design and sequenced 38 individuals from five families, under the hypothesis that families with multiple IBD-affected individuals harbor one or more risk variants that (i) are shared among affected family members, (ii) are rare and (iii) have substantial effect on disease development. Our analysis revealed not only novel candidate risk variants but also high polygenic risk scores for common known risk variants in four out of the five families. Functional analysis of our top novel variant in the remaining family, a rare missense mutation in the ubiquitin ligase TRIM11, suggests that it leads to increased nuclear factor of kappa light chain enhancer in B-cells (NF-κB) signaling. We conclude that an accumulation of common weak-effect variants accounts for the high incidence of IBD in most, but not all families we analyzed and that a family study design can identify novel rare variants conferring risk for IBD with potentially large effect size, such as the TRIM11 p.H414Y mutation.

1 March 2011 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
YWYan Wei
Yan Wei
JLJie Luo
Jie Luo
MRMax Robinson
Max Robinson
JEJimmy Eng
Jimmy Eng
RARuedi Aebersold
Ruedi Aebersold
JRJeffrey Ranish
Jeffrey Ranish
Biomedical research requires protein detection technology that is not only sensitive and quantitative, but that can reproducibly measure any set of proteins in a biological system in a high throughput manner. Here we report the development and application of a targeted proteomics platform termed index-ion triggered MS2ion quantification (iMSTIQ) that allows reproducible and accurate peptide quantification in complex mixtures. The key feature of iMSTIQ is an approach called index-ion triggered analysis (ITA) that permits the reproducible acquisition of full MS2 spectra of targeted peptides independent of their ion intensities. Accurate quantification is achieved by comparing the relative intensities of multiple pairs of fragment ions derived from isobaric targeted peptides during MS2 analysis. Importantly, the method takes advantage of the favorable performance characteristics of the LTQ-Orbitrap, which include high mass accuracy, resolution, and throughput. As such it provides an attractive targeted proteomics tool to meet the demands of systems biology research and biomarker studies.